Stock GID GI DYNAMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights GI Dynamics, Inc. Australian S.E.

Equities

GID

AU000000GID7

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Morphic Medical Inc. Receives Approval from the U.S. Food and Drug Administration for Amendments to Certain Requirements for Its Pivotal Study
CI
GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India
CI
GI Dynamics, Inc. Announces Final Data from the ENDO Trial, Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity
CI
GI Dynamics Inc. Announces Approval of the I-STEP Clinical Study in India
CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Gi Dynamics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Gi Dynamics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
CI
Gi Dynamics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
CI
Gi Dynamics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
GI Dynamics Inc Announces the First Patient in the United States Step-1 Clinical Trial Has Been Enrolled at Michigan Medicine in Ann Arbor, Michigan
CI
Gi Dynamics® Inc. Announces Positive EndoBarrier Data from University of Freiburg in Germany Showing Improvements of Cardiovascular Risk (CV) Biomarkers and Predicted 4-Year Risk of Major CV Events
CI
Gi Dynamics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
GI Dynamics, Inc. Presents Worldwide Endobarrier Registry Data for 871 Patients at EASD 2019
CI
Gi Dynamics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
CI
GI Dynamics Inc. Announces the Execution of its Contract with Surgical Specialists of Louisiana
CI
GI Dynamics Announces Lead Clinical Study Site for US Pivotal Trial of EndoBarrier
CI
GI Dynamics, Inc. Announces Enrolling Patients with Type 2 Diabetes and Obesity During the Second Half of 2019
CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019
CI
GI Dynamics, Inc. Announces Positive Results on One-Year Data from the Association of British Clinical Diabetologists Endobarrier Obstructive Sleep Apnea Study
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GIDYL Stock
  4. GID Stock
  5. News GI Dynamics, Inc.
  6. Highlights